Why the study?
Familial combined hyperlipidemia is an important cause of cardiovascular disease with high prevalence, making targeted treatment ideal, but this requires understanding patients' genetic background and underlying metabolic pathways.
Answers are grounded in this paper and cite their sources.
This review summarizes the molecular mechanisms, genetic background, and therapeutic strategies for familial combined hyperlipidemia.
Among different types of dyslipidemia, familial combined hyperlipidemia (FCHL) is the most common genetic disorder, which is characterized by at least two different forms of lipid abnormalities: hypercholesterolemia and hypertriglyceridemia. FCHL is an important cause of cardiovascular diseases. FCHL is a heterogeneous condition linked with some metabolic defects that are closely associated with FCHL. These metabolic features include dysfunctional adipose tissue, delayed clearance of triglyceride-rich lipoproteins, overproduction of very low-density lipoprotein and hepatic lipids, and defect in the clearance of low-density lipoprotein particles. There are also some genes associated with FCHL such as those affecting the metabolism and clearance of plasma lipoprotein particles. Due to the high prevalence of FCHL especially in cardiovascular patients, targeted treatment is ideal but this necessitates identification of the genetic background of patients. This review describes the metabolic pathways and associated genes that are implicated in FCHL pathogenesis. We also review existing and novel treatment options for FCHL.
No takes yet. Share an insight, caveat, or question.
Taghizadeh et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: